# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Study · id `cardio:ct-nct02787551` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02787551](<https://clinicaltrials.gov/study/NCT02787551>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02787551

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 514 participants.

## Technical summary

Registry record NCT02787551. Randomized; no masking; primary purpose treatment. Start 2016-07-06 (actual); primary completion 2018-05-25 (actual). Results posted on 2019-06-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 514 participants (enrolled count; ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Started: 2016-07-06 (actual) (ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Primary completion: 2018-05-25 (actual) (ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Completion: 2018-11-17 (actual) (ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Results first posted: 2019-06-12 (ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Countries: United States; Canada; Estonia; Germany; Israel; Italy; Romania; Slovakia; Spain (ClinicalTrials.gov record NCT02787551, source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02787551-2022-03-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Acronym: LixiLan-G
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine/lixisenatide fixed ratio combination
- Intervention (Drug): liraglutide
- Intervention (Drug): exenatide
- Intervention (Drug): exenatide extended-release
- Intervention (Drug): albiglutide
- Intervention (Drug): dulaglutide
- Intervention (Drug): Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial (`cardio:pubmed-31530665`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes (`cardio:pubmed-35257461`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c67b6c8b066b2b04547fc87b66535906f8481281385dcdf9e990356a922e70f7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
